|
(V128) |
CLK3 Deletion attenuates pathologic growth, transcriptional and metabolic reprogramming in HIF1α driven hypertrophic heart disease |
| |
|
J.-M. Dominguez, A. Sarre, E. Hagag, W. Krek, P. Mirtschink (Zürich, Lausanne, CH; Dresden) |
|
|
Diskussion |
|
(V129) |
HDAC inhibitors promote the repression of the myocyte enhancer factor 2 along with cardiomypcyte hypertrophy by hyperacetylation of 14-3-3 chaperones and nuclear accumulation of class II HDACs |
| |
|
D. Finke, L. H. Lehmann, L. Frischbier, S. Wieber, H. A. Katus, J. Backs (Heidelberg) |
|
|
Diskussion |
|
(V130) |
Exenatide increases CASK-expression in ventricular cardiomyocytes leading to decreased Calcium/calmodulin kinase II activity and sarcoplasmic reticulum Ca-leak |
| |
|
C.-M. Lücht, J. Mustroph, L. Schöberl, L. S. Maier, S. Wagner (Regensburg) |
|
|
Diskussion |
|
(V131) |
Determining and modeling of the cardiac protein-protein interaction network and interactome of the inotropic factor S100A1 by AP-MS/MS |
| |
|
M. Egger, M. Busch, H. A. Katus, P. Most (Heidelberg) |
|
|
Diskussion |
|
(V132) |
Rho-family GTPase 1 mediates cardiac hypertrophy via SRF-dependent signaling |
| |
|
A. Rangrez, A. Kluge, J. Pott, A. Bernt, R. Frauen, N. Frey, D. Frank (Kiel, Hamburg) |
|
|
Diskussion |
|
(V133) |
Direct monitoring of cAMP at cardiac ryanodine receptor reveals altered β2-adrenoceptor dependent regulation in hypertrophy |
| |
|
F. Berisha, K. Götz, J. W. Wegener, A. R. Marks, S. Lehnart, V. Nikolaev (Hamburg, Göttingen; New York, US) |
|
|
Diskussion |